Article
Nanotechnological applications for the treatment of neurodegenerative disorders.
University of the Witwatersrand, School of Neurosciences, Department of Neurology, Parktown, 2193, Johannesburg, South Africa.
Progress in Neurobiology (impact factor:
8.87).
06/2009;
88(4):272-85.
DOI:10.1016/j.pneurobio.2009.05.002
pp.272-85
Source: PubMed
-
Citations (0)
- Cited In (6)
-
Article: Internationally Indexed Journal
[show abstract] [hide abstract]
ABSTRACT: Parkinson disease (PD) is the second most common progressive neurodegenerative disorder due to loss neurons in SubstantiaNigra pars compacta. A number of medical and surgical treatments are currently available but the beneficial effects wear off with long term use and many native therapies have severe side effects. Hence novel therapeutic strategies continue to be in the developmental demand. Nanomedicine is an important medical application in Nanotechnology which shows promising future in drug delivery system in Parkinson disease. This review gives a glimpse about current treatment for PD and discuss about the Nano-particle based drug delivery which evades Blood-Brain Barrier. BBB stands as a gateway for drug targeting in the central nervous system. Various potential nanoparticles and nanosystems based therapies are explored and benefits are heaved out. Further with a set of well regulated guidelines, it would allow nanotechnology to be used within medicine safely and people could benefit from its attributes.International Journal of Pharma and Bio Sciences. 01/2013; 4(1):692-704. -
Article: In vitro and in vivo studies on gelatin-siloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain.
[show abstract] [hide abstract]
ABSTRACT: Nanobiotechnology can provide more efficient tools for diagnosis, targeted and personalized therapy, and increase the chances of brain tumor treatment being successful. Use of nanoparticles is a promising strategy for overcoming the blood-brain barrier and delivering drugs to the brain. Gelatin-siloxane (GS) nanoparticles modified with Tat peptide can enhance plasmid DNA transfection efficiency compared with a commercial reagent. SynB-PEG-GS nanoparticles are membrane-penetrable, and can cross the blood-brain barrier and deliver a drug to its target site in the brain. The efficiency of delivery was investigated in vivo and in vitro using brain capillary endothelial cells, a cocultured blood-brain barrier model, and a normal mouse model. Our study demonstrated that both SynB-PEG-GS and PEG-GS nanoparticles had a spherical shape and an average diameter of 150-200 nm. It was shown by MTT assay that SynB-PEG-GS nanoparticles had good biocompatibility with brain capillary endothelial cells. Cellular uptake by SynB-PEG-GS nanoparticles was higher than that for PEG-GS nanoparticles for all incubation periods. The amount of SynB-PEG-GS nanoparticles crossing the cocultured blood-brain barrier model was significantly higher than that of PEG-GS nanoparticles at all time points measured (P < 0.05). In animal testing, SynB-PEG-GS nanoparticle levels in the brain were significantly higher than those of PEG-GS nanoparticles at all time points measured (P < 0.01). In contrast with localization in the brain, PEG-GS nanoparticle levels were significantly higher than those of SynB-PEG-GS nanoparticles (P < 0.01) in the liver. This study indicates that SynB-PEG-GS nanoparticles have favorable properties with regard to morphology, size distribution, and toxicity. Moreover, the SynB-PEG-GS nanoparticles exhibited more efficient brain capillary endothelial cell uptake and improved crossing of the blood-brain barrier. Further, biodistribution studies of rhodamine-loaded nanoparticles demonstrated that modification with the SynB peptide could not only improve the ability of PEG-GS nanoparticles to evade capture in the reticuloendothelial system but also enhance their efficiency in crossing the blood-brain barrier.International Journal of Nanomedicine 01/2012; 7:1031-41. · 3.13 Impact Factor -
Article: Brain Drug Delivery Systems for Neurodegenerative Disorders.
[show abstract] [hide abstract]
ABSTRACT: Neurodegenerative disorders (NDs) are rapidly increasing as population ages. However, successful treatments for NDs have so far been limited and drug delivery to the brain remains one of the major challenges to overcome. There has recently been growing interest in the development of drug delivery systems (DDS) for local or systemic brain administration. DDS are able to improve the pharmacological and therapeutic properties of conventional drugs and reduce their side effects. The present review provides a concise overview of the recent advances made in the field of brain drug delivery for treating neurodegenerative disorders. Examples include polymeric micro and nanoparticles, lipidic nanoparticles, pegylated liposomes, microemulsions and nanogels that have been tested in experimental models of Parkinsons, Alzheimers and Hungtintons disease. Overall, the results reviewed here show that DDS have great potential for NDs treatment.Current pharmaceutical biotechnology 09/2012; · 3.40 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
adequate cyto-architecture restoration
clinical neuroscience
concise incursion
connection patterns
Conventional drug delivery systems
devices
explores
functional recovery
future applications
induce physiological responses
molecular level
nano-enabled drug delivery systems
Nanotechnology
neurodegenerative disorders
Parkinson's diseases
restrictive blood-brain barrier
review article
stimulating
